PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
PACB currently has 306M outstanding shares. with minimal authorized share overhang for future dilution. The company has diluted shareholders by 11.79% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 08, 2026 |
10-Q filing | 305.8M shares outstanding |
310M | 0 |
| Nov 06, 2025 |
10-Q filing | 300.8M shares outstanding |
300M | 0 |
| Aug 07, 2025 |
10-Q filing | 300.2M shares outstanding |
300M | 0 |
| May 12, 2025 |
10-Q filing | 296.9M shares outstanding |
300M | 0 |
| Mar 17, 2025 |
10-K filing | 288.4M shares outstanding |
290M | 0 |
| Nov 22, 2024 |
8-K filing: Pacific Biosciences of California, Inc. issued $200 million in aggregate principal amount of 1.50% Convertible Senior Notes due 2029, 20,451,570 shares of common stock, and made a $50 million cash payment in exchange for $459 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2028. |
270M | 0 |
| Nov 12, 2024 |
10-Q filing | 272.9M shares outstanding |
270M | 0 |
| Aug 09, 2024 |
10-Q filing | 272.4M shares outstanding |
270M | 0 |
| May 09, 2024 |
10-Q filing | 269.6M shares outstanding |
270M | 0 |
| Feb 28, 2024 |
10-K filing | 253.6M shares outstanding |
250M | 0 |
| Nov 03, 2023 |
10-Q filing | 255.0M shares outstanding |
260M | 0 |
| Aug 04, 2023 |
10-Q filing | 250.1M shares outstanding |
250M | 0 |
| Aug 02, 2023 |
8-K filing: The Company entered into a Merger Agreement to acquire Apton Biosystems, Inc. and will issue up to approximately 6.3 million shares of common stock to Apton Securityholders upon closing of the acquisition. Apton Securityholders will also be entitled to receive $25 million, which the Company may elect to pay in cash, shares of Common Stock or a combination of cash and shares of Common Stock. |
240M | 0 |
| May 04, 2023 |
10-Q filing | 242.0M shares outstanding |
240M | 0 |
| Feb 28, 2023 |
10-K filing | 224.6M shares outstanding |
220M | 0 |
| Jan 27, 2023 |
8-K filing: Pacific Biosciences of California, Inc. closed a public offering of 17,500,000 shares of common stock at $10.00 per share, and an additional 2,625,000 shares were sold upon the exercise of the underwriter's option, resulting in net proceeds of approximately $189.2 million. ($175.0M proceeds) |
230M | 0 |
| Nov 08, 2022 |
10-Q filing | 225.1M shares outstanding |
230M | 0 |
| Aug 08, 2022 |
10-Q filing | 224.5M shares outstanding |
220M | 0 |
| May 26, 2022 |
POS AM filing: This post-effective amendment deregisters securities of the Company registered under such Registration Statement that remain unsold as of the date hereof, if any. |
220M | 0 |
| May 06, 2022 |
10-Q filing | 222.3M shares outstanding |
220M | 0 |
| Feb 28, 2022 |
10-K filing | 204.1M shares outstanding |
200M | 0 |
| Nov 05, 2021 |
10-Q filing | 215.1M shares outstanding |
220M | 0 |
| Sep 20, 2021 |
8-K filing: The company completed a private placement of 11,214,953 shares of common stock at $26.75 per share, resulting in gross proceeds of approximately $300 million. ($300.0M proceeds) |
200M | 0 |
| Aug 06, 2021 |
10-Q filing | 198.6M shares outstanding |
200M | 0 |
| May 06, 2021 |
10-Q filing | 194.8M shares outstanding |
190M | 0 |
| Feb 26, 2021 |
10-K filing | 175.0M shares outstanding |
170M | 0 |
| Nov 03, 2020 |
10-Q filing | 180.2M shares outstanding |
180M | 0 |
| Aug 06, 2020 |
10-Q filing | 154.4M shares outstanding |
150M | 0 |
| Jun 30, 2020 |
S-3/A filing: Pacific Biosciences of California, Inc. is filing an S-3/A form to register securities for potential sale, with an aggregate offering price not to exceed $250,000,000. |
150M | 0 |
| Jun 10, 2020 |
S-3 filing: Pacific Biosciences of California, Inc. is offering securities, including common stock, preferred stock, and debt securities, up to an aggregate offering price of $250,000,000. |
150M | 0 |
| May 08, 2020 |
10-Q filing | 153.5M shares outstanding |
150M | 0 |
| Feb 28, 2020 |
10-K filing | 153.1M shares outstanding |
150M | 0 |